Evidence map›Paper›PMID 29046716›Full record

ArticleChild and adolescent psychiatry and mental health2017

A multi-national comparison of antipsychotic drug use in children and adolescents, 2005-2012.

Luuk J Kalverdijk, Christian J Bachmann, Lise Aagaard, Mehmet Burcu, Gerd Glaeske, Falk Hoffmann, Irene Petersen, Catharina C M Schuiling-Veninga, Linda P Wijlaars, Julie M Zito

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Child and adolescent psychiatry and mental health, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 5 pooled it
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 5 syntheses or guidelines pooled it, 71 citations in OpenAlex.

  1. Pooled it
  2. Metabolic adverse effects of off-label use of second-generation antipsychotics in the adult population: a systematic review and meta-analysis.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2022
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 4 countries.

Luuk J KalverdijkDepartment of Psychiatry, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Christian J BachmannFreelance Researcher, Marburg, Germany.
Lise AagaardLife Science Team, IP & Technology, Bech-Bruun Law Firm, Copenhagen, Denmark.
Mehmet BurcuDepartment of Pharmaceutical Health Services Research, University of Maryland, Baltimore, MD USA.
Gerd GlaeskeDivision of Health Long-term Care and Pensions, University of Bremen, SOCIUM Research Center on Inequality and Social Policy, Bremen, Germany.
Falk HoffmannDepartment of Health Services Research, Carl von Ossietzky University, Oldenburg, Germany.
Irene PetersenDepartment of Primary Care and Population Health, University College London, London, UK.
Catharina C M Schuiling-VeningaUniversity of Groningen, Pharmacotherapy, Epidemiology & Economics, Groningen, The Netherlands.
Linda P WijlaarsDepartment of Primary Care and Population Health, University College London, London, UK.
Julie M ZitoDepartment of Pharmaceutical Health Services Research, University of Maryland, Baltimore, MD USA.
University of Groningen · NLUniversity of Maryland, Baltimore · USCarl von Ossietzky Universität Oldenburg · DEGreat Ormond Street Hospital · GBPhilipps University of Marburg · DEUniversity College London · GBUniversity of Bremen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over the last decades, an increase in antipsychotic (AP) prescribing and a shift from first-generation antipsychotics (FGA) to second-generation antipsychotics (SGA) among youth have been reported. However, most AP prescriptions for youth are off-label, and there are worrying long-term safety data in youth. The objective of this study was to assess multinational trends in AP use among children and adolescents. A repeated cross-sectional design was applied to cohorts from varied sources from Denmark, Germany, the Netherlands, the United Kingdom (UK) and the United States (US) for calendar years 2005/2006-2012. The annual prevalence of AP use was assessed, stratified by age group, sex and subclass (FGA/SGA). The prevalence of AP use increased from 0.78 to 1.03% in the Netherlands' data, from 0.26 to 0.48% in the Danish cohort, from 0.23 to 0.32% in the German cohort, and from 0.1 to 0.14% in the UK cohort. In the US cohort, AP use decreased from 0.94 to 0.79%. In the US cohort, nearly all ATP dispensings were for SGA, while among the European cohorts the proportion of SGA dispensings grew to nearly 75% of all AP dispensings. With the exception of the Netherlands, AP use prevalence was highest in 15-19 year-olds. So, from 2005/6 to 2012, AP use prevalence increased in all youth cohorts from European countries and decreased in the US cohort. SGA were favoured in all countries' cohorts.

Indexed as

AdolescentsAntipsychotic drugsAtypicalChildrenDenmarkGermanyNetherlandsPharmacoepidemiologyUKUSA

Identifiers

PMID29046716
PMCPMC5637352
OpenAlexW2762520970

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.